Breast diseases

PubMed Free Full Text

Breast cancer treatment: aromatase inhibitors

Canada

• Current Oncology
  • Endocrine therapy for postmenopausal women with hormone receptor–positive her2–negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement [2013]

China

• OncoTargets and Therapy
  • Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective [2016]

International

• Cochrane Database of Systematic Reviews
  • Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer [2022]

• Current Oncology
  • Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis [2023]

• Journal of Bone Oncology
  • Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG [2017]

Lithuania

• Medicina
  • Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer: A consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians [2014]

United States

• American College of Obstetricians and Gynecologists
  • Aromatase Inhibitors in Gynecologic Practice [2018]

• Clinical Cardiology
  • Are Aromatase Inhibitors Associated with Higher Myocardial Infarction Risk in Breast Cancer Patients? A Medicare Population-Based Study [2018]

{Related topics}

• Topic
  • Breast cancer treatment